These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 16415900

  • 21. Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning.
    Kalpoe JS, van der Heiden PL, Vaessen N, Claas EC, Barge RM, Kroes AC.
    Bone Marrow Transplant; 2007 Jul; 40(2):137-43. PubMed ID: 17530007
    [Abstract] [Full Text] [Related]

  • 22. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation.
    Meijer E, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK, Verdonck LF.
    Transpl Infect Dis; 2004 Dec; 6(4):171-8. PubMed ID: 15762935
    [Abstract] [Full Text] [Related]

  • 23. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
    Brown JR, Kim HT, Li S, Stephans K, Fisher DC, Cutler C, Ho V, Lee SJ, Milford EL, Ritz J, Antin JH, Soiffer RJ, Gribben JG, Alyea EP.
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
    [Abstract] [Full Text] [Related]

  • 24. Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation.
    Zhu KE, Hu JY, Zhang T, Chen J, Zhong J, Lu YH.
    Eur J Haematol; 2008 Dec; 81(6):461-6. PubMed ID: 18774951
    [Abstract] [Full Text] [Related]

  • 25. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.
    Robin M, Porcher R, De Castro Araujo R, de Latour RP, Devergie A, Rocha V, Larghero J, Adès L, Ribaud P, Mary JY, Socié G.
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1304-12. PubMed ID: 17950917
    [Abstract] [Full Text] [Related]

  • 26. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
    Remberger M, Mattsson J, Hassan Z, Karlsson N, LeBlanc K, Omazic B, Okas M, Sairafi D, Ringdén O.
    Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
    [Abstract] [Full Text] [Related]

  • 27. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM.
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [Abstract] [Full Text] [Related]

  • 28. Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning.
    Willems E, Baron F, Seidel L, Frère P, Fillet G, Beguin Y.
    Bone Marrow Transplant; 2010 Apr; 45(4):689-93. PubMed ID: 19718063
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation.
    Labbé AC, Su SH, Laverdière M, Pépin J, Patiño C, Cohen S, Kiss T, Lachance S, Sauvageau G, Busque L, Roy DC, Roy J.
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1192-200. PubMed ID: 17889356
    [Abstract] [Full Text] [Related]

  • 31. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning.
    Uzunel M, Remberger M, Sairafi D, Hassan Z, Mattsson J, Omazic B, Barkholt L, Ringdén O.
    Transplantation; 2006 Oct 15; 82(7):913-9. PubMed ID: 17038906
    [Abstract] [Full Text] [Related]

  • 32. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation.
    Belkacémi Y, Labopin M, Hennequin C, Hoffstetter S, Mungai R, Wygoda M, Lundell M, Finke J, Aktinson C, Lorchel F, Durdux C, Basara N.
    Int J Radiat Oncol Biol Phys; 2007 Feb 01; 67(2):544-51. PubMed ID: 17141976
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V, Ugur A, Colak D, Saba R, Tezcan G, Kupesiz A, Karadogan I, Gultekin M, Yesilipek A, Undar L.
    Jpn J Infect Dis; 2006 Aug 01; 59(4):216-21. PubMed ID: 16936338
    [Abstract] [Full Text] [Related]

  • 35. Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection.
    Qamruddin AO, Oppenheim BA, Guiver M, Mutton KJ, Chopra R.
    Bone Marrow Transplant; 2001 Feb 01; 27(3):301-6. PubMed ID: 11277178
    [Abstract] [Full Text] [Related]

  • 36. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
    Nakamura R, Rodriguez R, Palmer J, Stein A, Naing A, Tsai N, Chang K, Slovak ML, Bhatia R, Spielberger R, Kogut N, Pullarkat V, Kirschbaum M, Forman SJ, O'Donnell MR.
    Bone Marrow Transplant; 2007 Nov 01; 40(9):843-50. PubMed ID: 17724447
    [Abstract] [Full Text] [Related]

  • 37. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
    Nakamae H, Yamane T, Hasegawa T, Nakamae M, Terada Y, Hagihara K, Ohta K, Hino M.
    Am J Hematol; 2006 Jul 01; 81(7):525-31. PubMed ID: 16755559
    [Abstract] [Full Text] [Related]

  • 38. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T, Aisa Y, Watanabe R, Yamazaki R, Kato J, Shimizu T, Shigematsu N, Kubo A, Yajima T, Hibi T, Ikeda Y, Okamoto S.
    Biol Blood Marrow Transplant; 2008 Jun 01; 14(6):651-7. PubMed ID: 18489990
    [Abstract] [Full Text] [Related]

  • 39. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E, Koza V, Vítek A, Mayer J, Sedlácek P, Zák P, Zapletalová J, Benesová K, Krejcová H, Steinerová K, Maresová I, Cetkovský P.
    Vnitr Lek; 2006 Dec 01; 52(12):1172-80. PubMed ID: 17299910
    [Abstract] [Full Text] [Related]

  • 40. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.
    Biol Blood Marrow Transplant; 2009 Jan 01; 15(1):30-8. PubMed ID: 19135940
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.